Journal
VACCINE
Volume 23, Issue 8, Pages 1029-1036Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2004.07.043
Keywords
influenza vaccine; adenovirus vector; noninvasive vaccine
Categories
Funding
- NIAID NIH HHS [1-R43-AI-43802] Funding Source: Medline
Ask authors/readers for more resources
The increasing number and density of the human population, the emergence of lethal influenza strains, and the potential use of designer influenza virus as a bioweapon, collectively highlight a critical need for more rapid production of influenza vaccines and less invasive means of delivery. We have developed a nonreplicative adenovirus-vectored influenza vaccine that can be produced without the prerequisite of growing influenza virus. This new class of vaccines can be administered as a nasal spray or skin patch by personnel without medical training. We report here that adenovirus-vectored nasal and epicutaneous influenza vaccines were well tolerated by human volunteers. The nasal vaccine. was more potent than its epicutaneous counterpart under the adjuvant-free experimental condition. These results pro-tide the foundation for further human testing of needleless vectored vaccines as promising alternatives to current vaccines. (C) 2004 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available